Skip to main content
. 2021 Nov 24;12:718763. doi: 10.3389/fphar.2021.718763

FIGURE 3.

FIGURE 3

Presentation of the prevalence of TDR. Note: NRTIs, nucleoside reverse transcriptase inhibitors; NNRTIs, nonnucleoside reverse transcriptase inhibitors; PIs, protease inhibitors; INIs, integrase inhibitors; TDR, transmitted drug resistance.